top of page

156-158 PACIFIC HIGHWAY, GREENWICH, NSW 2065

(02) 8061 4048

What do I need to know about Rhenium-SCT® (skin cancer therapy)?1-5

Rhenium-SCT® (Skin Cancer Therapy) is a brachytherapy utilising the Beta emitter radioisotope Rhenium-188 for the treatment Non-Melanoma Skin Cancer. 

Rhenium-SCT® is approved in Europe, South Africa and Australia for the treatment of basal and squamous cell carcinomas of the skin.

In general, Rhenium-SCT® can be applied to any location on the body. It can be applied to single and/or multiple lesions of almost any shape or size in just one session. It is also suitable for patients of any age as well as patients with previously treated or complicated lesions.

The Rhenium-SCT® is not recommended for minors or pregnant patients.

Precise3,4**

**Accurate dosing. Spares healthy tissue.

Painless1,3‡

‡No reported pain

Non-Invasive1

†A procedure is considered non-invasive when no break or cut in the skin is created.

Single-Session1-3*

*Complete tumour regression in 98.5% of lesions treated3

Aesthetic/Functional1,4§

§No disfiguring scarring; Retained functionality in high-risk and difficult to treat areas.

Rhenium-SCT demonstration video

Fees and charges

SBG is a licenced provider of radioisotope therapy, and along with VMOs, provides dermal brachytherapy services for Non-Melanoma Skin Cancers (NMSC). Fees charged by all VMOs are set independently and are generally below Australian Medical Association (AMA) rates. However, due to the technical and manufacturing expertise required to produce radioisotopes, the cost of treating a single small lesion in the vicinity of a critical structure, such as face, eyes, nose or ears, should be quoted at around $7,000 to $8,000 (AUD). The inclusion of this treatment as a rebateable item in Medicare and private health funds has not yet been finalised, and as such there is currently no rebate. This means that a single treatment will be of $7,000 to $8,000 (AUD). 

SBG, as an accredited radioisotope facility, can provide services to the VMOs on a similar basis as a surgeon is provided services at a hospital grade facility.

Frequently asked questions
SBG Logo White+Green.png

ADDRESS

LEVEL 3, SUITE 304,

156-158 PACIFIC HIGHWAY
GREENWICH, NSW
Australia 2065

OPENING HOURS

Monday - Friday: 9:00am – 5:00pm

Treatment Enquiry

Please take a moment to fill out the form.

Thanks for submitting!

REFERENCES: 1. Castellucci P, et al. High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results. Eur J Nucl Med Mol Imaging. 2021;48(5):1511-1521. doi: 10.1007/s00259-020-05088-z. 2. Cipriani C, et al. Epidermal Radionuclide Therapy - Dermatological High-Dose-Rate. Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma. In: Therapeutic Nuclear Medicine, editor Baum RP; New York: Springer, 2014. 3. Cipriani C, et al. Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study. J Dermatolog Treat. 2020:1-7. doi: 10.1080/09546634.2020.1793890. 4. Cipriani C, et al. Personalized high-dose-rate brachytherapy with non-sealed rhenium-188 in non-melanoma skin cancer. Int J Nucl Med. 2017;114–112. 5. Data on file. OncoBeta Garching, Germany.

Rhenium-SCT® and OncoBeta® is trademark of OncoBeta GmbH.

Copyright © 2022. Sydney Brachytherapy Group.

bottom of page